SE464796B - Komposition avsedd att minska oeverviktstillstaand hos daeggdjur innehaallande pyruvat och dihydroxiaceton - Google Patents

Komposition avsedd att minska oeverviktstillstaand hos daeggdjur innehaallande pyruvat och dihydroxiaceton

Info

Publication number
SE464796B
SE464796B SE8202064A SE8202064A SE464796B SE 464796 B SE464796 B SE 464796B SE 8202064 A SE8202064 A SE 8202064A SE 8202064 A SE8202064 A SE 8202064A SE 464796 B SE464796 B SE 464796B
Authority
SE
Sweden
Prior art keywords
group
rats
diet
effect
pyruvate
Prior art date
Application number
SE8202064A
Other languages
English (en)
Swedish (sv)
Other versions
SE8202064L (sv
Inventor
R T Stanko
Original Assignee
Montefiore Hospital & Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/249,812 external-priority patent/US4351835A/en
Application filed by Montefiore Hospital & Medica filed Critical Montefiore Hospital & Medica
Publication of SE8202064L publication Critical patent/SE8202064L/xx
Publication of SE464796B publication Critical patent/SE464796B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8202064A 1981-04-01 1982-03-31 Komposition avsedd att minska oeverviktstillstaand hos daeggdjur innehaallande pyruvat och dihydroxiaceton SE464796B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/249,812 US4351835A (en) 1981-04-01 1981-04-01 Method for preventing body fat deposition in mammals
US06/346,181 US4415576A (en) 1981-04-01 1982-02-09 Method for preventing body fat deposition in mammals

Publications (2)

Publication Number Publication Date
SE8202064L SE8202064L (sv) 1982-10-02
SE464796B true SE464796B (sv) 1991-06-17

Family

ID=26940368

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8202064A SE464796B (sv) 1981-04-01 1982-03-31 Komposition avsedd att minska oeverviktstillstaand hos daeggdjur innehaallande pyruvat och dihydroxiaceton

Country Status (8)

Country Link
US (1) US4415576A (de)
CA (1) CA1176981A (de)
CH (1) CH653891A5 (de)
DE (1) DE3211587A1 (de)
FI (1) FI821119L (de)
GB (1) GB2095555B (de)
PT (1) PT74686A (de)
SE (1) SE464796B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4548937A (en) * 1981-04-01 1985-10-22 Montefiore Hospital Method for preventing body fat deposition in mammals
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5692302A (en) * 1991-03-01 1997-12-02 Warner-Lambert Company Razor cartridges comprising wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5646190A (en) * 1991-03-01 1997-07-08 Warner-Lambert Company Acne treating-wound healing compositions and methods for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5614561A (en) * 1991-03-01 1997-03-25 Warner-Lambert Company Antihistamine-wound healing compositions and methods for preparing and using same
US5641814A (en) * 1991-03-01 1997-06-24 Warner-Lambert Company Antikeratolytic-wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5403921A (en) * 1993-04-30 1995-04-04 University Of New Mexico Exercise hydration regimen to enhance exercise endurance and performance
US5612374A (en) * 1994-02-14 1997-03-18 Ronald T. Stanko Inhibiting growth of mammary adenocarcinoma
US5480909A (en) * 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5801198A (en) * 1995-07-13 1998-09-01 University Of Pittsburgh Medical Center Retarding neutrophil infiltration ad morphologic reduction in ischemic bowel tissues
MX9703653A (es) * 1995-09-19 1998-07-31 Cellular Sciences Inc Composicion y metodo para tratar enfermedades mamiferas ocasionadas por la respuesta inflamatoria.
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US5886040A (en) * 1997-06-17 1999-03-23 Amt Labs, Inc. Creatine pyruvate salt with enhanced palatability
DE19729786A1 (de) * 1997-07-11 1999-01-14 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von Calciumpyruvaten
US6177576B1 (en) 1997-08-05 2001-01-23 Michael J. Arnold Pyruvate saccaride ketals
US5876763A (en) * 1998-05-26 1999-03-02 University Of New Mexico Glycerol enhanced rehydration formulation
DE19836450A1 (de) * 1998-08-12 2000-02-17 Sueddeutsche Kalkstickstoff Stabile, Brenztraubensäure (Salze) enthaltende Formulierung für die Tierernährung
US6846842B2 (en) 1999-10-07 2005-01-25 Beth Israel Deconess Medical Center, Inc. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
JP2004527529A (ja) * 2001-04-04 2004-09-09 クリティカル セラピューティックス インコーポレイテッド 急性腎不全を予防するための方法
CA2481753A1 (en) * 2002-04-17 2003-10-30 Critical Therapeutics, Inc. Method for treating ileus with an alpha -ketoalkanoic acid or - ester or - amide
AU2007238938B2 (en) 2006-04-12 2013-05-23 Ranya L. Alexander Compositions comprising pyruvate alkyl esters and uses thereof
US20200237815A1 (en) 2017-02-24 2020-07-30 Alain Martin Methods for treatment of lung damage and for inhibition of lung fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158057A (en) * 1975-03-28 1979-06-12 Stanko Ronald T Prevention of the accumulation of fatty deposits in the liver
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals

Also Published As

Publication number Publication date
GB2095555A (en) 1982-10-06
US4415576A (en) 1983-11-15
PT74686A (en) 1982-05-01
FI821119L (fi) 1982-10-02
DE3211587A1 (de) 1982-10-28
SE8202064L (sv) 1982-10-02
FI821119A0 (fi) 1982-03-31
CA1176981A (en) 1984-10-30
CH653891A5 (de) 1986-01-31
GB2095555B (en) 1985-10-16

Similar Documents

Publication Publication Date Title
SE464796B (sv) Komposition avsedd att minska oeverviktstillstaand hos daeggdjur innehaallande pyruvat och dihydroxiaceton
US4351835A (en) Method for preventing body fat deposition in mammals
US4645764A (en) Method for preventing body fat deposition in animals
LONG III et al. Effect of carbohydrate and fat intake on nitrogen excretion during total intravenous feeding
Vetrichelvan et al. Anti-diabetic activity of alcoholic extract of Celosia argentea L INN. seeds in rats
EP0007691B1 (de) Zusammensetzungen zur Verwendung bei der Verminderung des Appetites auf Kohlenhydratkalorien
Brown et al. Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of Δ9-tetrahydrocannabinol
Morrison et al. Vitamin absorption studies: I. Factors influencing the excretion of oral test doses of thiamine and riboflavin by human subjects
Sugimura et al. Quantitative nutritional studies with water-soluble, chemically defined diets. VII. Nitrogen balance in normal and tumor-bearing rats following forced feeding
Booth et al. Ontogeny and insulin-dependence of the satiation which follows carbohydrate absorption in the rat
Blumenkrantz et al. Total parenteral nutrition in the management of acute renal failure
US4594249A (en) Method of altering intoxicating effects of alcohol
KRALL et al. Clinical evaluation of formamidinyliminourea, a new biguanide oral blood sugar lowering compound: comparison with other hypoglycemic agents
Thomsen et al. Long-term lithium administration to rats
US6159986A (en) Compounds and therapy for resisting memory loss in humans
SLATER et al. Adrenal ascorbic acid, plasma and adrenal corticoid response to fasting in young rats
Hahn et al. The effects of catecholamines, glucagon, and diet on enzyme activities in brown fat and liver of the rat
Mendelson et al. Puromycin inhibition of ethanol ingestion and liver alcohol dehydrogenase activity in the rat
Sankaran et al. Enteral macronutrients abolish high blood alcohol levels in chronic alcoholic rats
US20120231098A1 (en) Weight loss composition
JP3380287B2 (ja) 血中アルコール濃度上昇阻害飲料
Holck et al. Effects of disulfiram on growth, longevity, and reproduction of the albino rat
RU2057463C1 (ru) Биологически активная пищевая добавка "женьшень стимул"
BEARD et al. PHYSIOLOGIC SIGNIFICANCE OF THE CREATININE COEFFICIENT AND THE CREATINE TOLERANCE TEST: A CRITICAL REVIEW
NZ200088A (en) Control of weight gain in non-human mammals with pyruvate and dihydroxyacetone

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8202064-5

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8202064-5

Format of ref document f/p: F